Dr Lal Pathlabs, Metropolis shares gain on Kotak Equities’ rating upgrades, target price raise
After a long stretch of stock underperformance, domestic brokerage Kotak Institutional Equities stated in its most recent report that it has double upgraded Dr Lal Pathlabs from Sell to Add with an increased fair value of ₹2,360. Given reasonable prices, the brokerage has also increased Metropolis Healthcare’s fair value to ₹1,600, keeping its Reduce rating. Following … Read more